Centene's (CNC) Q3 beat supports its ongoing earnings recovery, RBC Capital Markets said in a note emailed Friday.
In late October, the company reported Q3 adjusted earnings of $0.58 per diluted share. Analysts polled by FactSet expected $0.10. Revenue for the quarter was $50.65 billion. Analysts expected $47.12 billion.
The analysts said the company's Medicare Advantage business reached breakeven a year ahead of plan, while its prescription drug plan business delivering mid-to-high 3% margins.
Looking ahead to 2027, management expects about $0.50 in 2026 earnings items that will not recur, providing a starting point of roughly $4.70, the analysts said, adding that uncertainties remain around membership losses related to the One Big Beautiful Bill Act.
"Following a deeply disruptive 2025, CNC enters 2026 with clear early evidence of a multi-year earnings recovery," the analysts said.
RBC raised its price target on Centene to $73 from $71 while keeping its sector perform rating.
Price: 65.00, Change: -0.58, Percent Change: -0.88
Comments